Difference in Venous Thromboembolism Risk between Combination 17β-Estradiol/ Progesterone (E2/P4) and Conjugated Equine Estrogen/ Medroxyprogesterone Acetate (CEE/MPA) as Assessed by US Claims Data

Difference in Venous Thromboembolism Risk between Combination 17β-Estradiol/ Progesterone (E2/P4) and Conjugated Equine Estrogen/ Medroxyprogesterone Acetate (CEE/MPA) as Assessed by US Claims Data Meeting Abstract

sustainable development goals

publication date

December 1, 2022

webpage

Web of Science

published in

MENOPAUSE-THE JOURNAL OF THE MENOPAUSE SOCIETY Journal

start page

1453

end page

1453

volume

29

issue

12